The 15 billion cataract treatment market needs to be freed from import dependence

Recently, since the media article caused Sapp Ess eye drops (saccharine eye drops) into the vortex of questions about efficacy and publicity, the article pointed directly at the brainwashing marketing of Sapp Ess eye drops, saying it delays the treatment of cataract patients.
no drug has been found to be effective in treating or delaying the progression of cataracts, the American Society of Ophthalmology wrote in its 2016 Clinical Guidelines for Adult Cataracts. At present, the global consensus among ophthalmologists on the treatment of cataracts is surgical treatment. According to the National Health and Planning Commission's national defense blind website, surgical treatment is the most effective means, regardless of cataracts.most effective surgical treatment
cataracts are the most common geriatric eye diseases, the main symptoms are visual impairment, which is related to the turbidity and location of the lens. Cataracts have long been one of the leading causes of blindness. China now has the world's largest cataract population, with about 60 million people, or a third of the world's total. Cataract prevalence is over 46 per cent among people over 60 years of age, and the number is rising. Surgical treatment is the most effective way to treat cataracts in old age, but for Chinese patients, the proportion of patients undergoing rehabilitation surgery is low, compared with developed countries, there is a large gap.
According to the 13th Five-Year Plan for Eye Health (2016-2020) issued by the General Office of the National Health and Family Planning Commission, the rate of cataract surgery (CSR) in China exceeded 1,500 cases per million people in 2015, an increase of 56% over the end of the 11th Five-Year Plan, but still far from the more than 9,000 cases/million of people/year in developed countries. This aspect stems from the lack of understanding of standardized treatment, on the other hand, it stems from the fact that patients often face the burden of high cost of imported surgical products.
, it is understood that artificial lens is a special lens made of synthetic materials, is the most important material for surgical treatment of cataracts. By surgically removing the turbid crystals of cataract patients and implanting artificial lenses into the eye to replace the original lenses, cataract patients can restore their vision.
the number of cataracts and the number of operations increases year by year, the greater the demand for artificial crystals used in surgery. About 2.3 million cataract operations are carried out in China each year, of which 30% of the patients are still using hard artificial crystals that have been eliminated abroad, the proportion of imported brands of soft artificial crystals used in clinical use is more than 90%, and the gap between domestic and import markets is huge. It is expected that by 2020, the annual number of cataract operations in China will reach 4 million, and the clinical treatment of eye diseases in China will be in great demand.
According to relevant statistics, the size of China's cataract industry in 2016 has been close to 15 billion yuan, and the use of ophthalmology supplies are currently mostly dependent on imports, the local ophthalmology industry compared with developed countries are still lagging behind, China's cataract surgery rate is still low. With the introduction of new technology and the development of the whole industry, the research and development of domestic high-quality and reasonably priced medical supplies has become the direction of efforts in the great era.drug market is concentrated in retail terminals
the pathogenesis of cataracts mainly includes old-age cataracts, diabetic cataracts, radiation and trauma caused by cataracts. At present, there are about ten kinds of cataract drugs in China.
according to sample hospital statistics, in 2016 cataract drug sales of 14.48 million yuan, the main varieties are: Ninoxin (sample hospital sales of 7.31 million yuan, the same between), blind eye (35 10,000 yuan), ammonia iodine peptide (1.72 million yuan), pythaltamate (1.25 million yuan), glutathione (530,000 yuan), and facolin and compound thyroxine /iodine ceronen, etc. In recent years, the cataract drug market competition has become increasingly fierce, but the overall market size of sample hospitals is small, which is mainly related to the small number of ophthalmology hospitals in sampling.
In terms of dosage form, sales of cataract drug eye drops in sample hospitals in 2016 were 9.94 million yuan, accounting for 68.9%, capsule sales were 2.36 million yuan, accounting for 16.3%, tablet sales were 1.15 million yuan, accounting for 7.9%, and injection sales were 1.04 million yuan, accounting for 7.2%. Among them, eye drops occupy an absolute advantage. Since cataract drug eye drops are mostly OTC drugs, the market is mainly concentrated in retail terminals, so the overall market size of sample hospitals is small.
2016, there were nearly 20 cataract drug manufacturers involved in the sample hospitals, with sales of the top 5 enterprises totaling 12.4 million yuan, accounting for 85.7% of the overall market, with a more concentrated market. The top 5 companies are: Sunsan (sample hospital sales of 6.27 million yuan, accounting for 45.7%, the same between), Hunan Tianji Grasstang Pharmaceuticals (2.22 million yuan, or 15.3%), Zhejiang Guoguang Pharmaceuticals (1.7 million yuan, or 11.7%), Guangzhou Zhongyuan Pharmaceuticals (1.15 million yuan, or 7.9%), Changchun Price Pharmaceuticals (720,000 yuan, or 5.%). (Medical Economics)